logo
episode-header-image
Mar 2024
7m 50s

Eli Lilly CEO Dave Ricks Talks Fighting ...

bloomberg
About this episode

Eli Lilly CEO Dave Ricks says the company is working on expanding its medicine supply as the global obesity rate increases. Speaking with Bloomberg's Caroline Hyde at the Economic Club of New York, the head of the pharma giant says that they are looking to create an oral tablet in addition to an injectable device and hopes to get them to the market quicker. 

See omnystudio.com/listener for privacy information.

Up next
Today
Chris Phelan Talks October CPI, Oil Prices
White House Council of Economic Advisers Chairman Chris Phelan states the October CPI report was "not a good number," and inflation came in hot. But he still says raising interest rates by 50 basis points would be premature. He speaks with Bloomberg's Dani Burger and Isabelle Lee ... Show More
7m 4s
Today
PIMCO's Tiffany Wilding Talks CPI, Rate Hike Debate
Federal Reserve Governor Christopher Waller on Tuesday lit up debate around a possible half-percentage-point interest rate increase by the central bank in December after inflation data came in hotter than expected. PIMCO Economist Tiffany Wilding discusses Waller's comments and r ... Show More
6m 2s
Today
Constance Hunter Talks Core CPI
Constance Hunter, Chief Economist & Head of Research at Economist Enterprise, breaks down today's CPI report with Bloomberg's Tom Keene and Damian Sassower. The consumer price index, excluding food and energy, rose 0.3% from a month earlier, topping estimates for a third straight ... Show More
5m 17s
Recommended Episodes
Jan 2025
Dave Ricks
Eli Lilly is the world's most valuable drug company, known for its blockbuster anti-obesity drugs that's transforming America. In an episode of "The David Rubenstein Show: Peer to Peer Conversations," CEO Dave Ricks talks about how the company will begin studies this year to see ... Show More
22m 38s
Feb 2025
Eli Lilly CEO: The Weight-Loss Drug Revolution, AI in Pharma, and Innovation
<p>Nicolai Tangen meets with David Ricks, CEO of&nbsp;Eli&nbsp;Lilly, for a discussion about the pharmaceutical giant's remarkable journey. At the forefront is&nbsp;Eli&nbsp;Lilly's breakthrough work with weight reduction drugs, which are showing promise far beyond their original ... Show More
55m 40s
Feb 2024
The obesity drug craze is entering its next phase
Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ... Show More
22m 46s
Apr 2024
Money Talks: Why weight-loss drugs will reshape the world
<p>More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ... Show More
36m 59s
Apr 2025
ICYMI: Eli Lilly's New Weight Loss Pill
Shares in Eli Lilly surged on Friday  after its experimental pill helped patients shed weight and control blood sugar about as well as Ozempic, an advance that could turbocharge what’s already one of the fastest growing markets in medicine. Shares of the drug’s originator Chugai ... Show More
7m 16s
Sep 2025
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
<p>(0:00) Introducing Eli Lilly CEO Dave Ricks</p> <p>(1:43) How Eli Lilly discovered the GLP-1 impact on weight loss, counterfeit products from China</p> <p>(7:08) GLP-1 pricing and capital allocation after a breakout pharma product</p> <p>(12:56) Why Biotech VC has plummeted, " ... Show More
30m 40s
Aug 2024
Market Rally Aims for “Cloud Nine,” Bronfman's Paramount Bid, Eli Lilly CEO on Weight-Loss Drug 8/20/24
<p>Carl Quintanilla and Jim Cramer led off the show by delving into the broadening market rally, as the S&P 500 and Nasdaq aim for a ninth consecutive day of gains. David Faber called into the show with reporting on Edgar Bronfman's bid to acquire Paramount Global. Eli Lilly CEO ... Show More
44m 46s
Apr 2024
Money Talks: Why weight-loss drugs will reshape the world
More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ... Show More
36m 59s
Aug 2025
Deep Dive: Novo Nordisk & Eli Lilly Stumble Into Next Phase of Ozempic Era
Two pharma giants, Eli Lilly and Novo Nordisk, are in a high-stakes race for leadership in the $150 billion GLP-1 obesity drug market. We examine Lilly’s latest earnings, the mixed results from its oral pill orforglipron, and Novo’s push with higher-dose oral semaglutide. We also ... Show More
11m 3s